Teva renonce à contester le brevet de Novartis et ne lancera pas de générique de l’acide zolédronique aux Etats-Unis avant l’expiration de ce brevet en mars 2013.
Teva has dropped the challenge against the Novartis patent and will not launch zoledronic acid in the US until after the Zometa and Reclast patent expires in March 2013.
